These results suggest that MALAT1 gene expression levels in EBC samples, in addition to the tumor tissue, peripheral blood, and serum exosomes, can be used as a tumor biomarker for the diagnosis and follow-up of NSCLC. This evidence concerns the gene MALAT1 and neoplasm.